Organization
Ohio State University Wexner Medical Center
28 abstracts
Abstract
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).Org: Prelude Therapeutics Incorporated, Washington University School of Medicine, Sarah Cannon Research Institute at HealthONE, Florida Cancer Specialists/Sarah Cannon Research Institute, Prelude Therapeutics, Inc.,
Abstract
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.Org: O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Clinical Trial Development Division, Roswell Park Comprehensive Cancer Center, Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center,
Abstract
Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients.Org: University of Kentucky, Ohio State University Wexner Medical Center, Ohio State University James Cancer Hospital Department of Radiation Oncology, Roswell Park Comprehensive Cancer Center, Moffitt Cancer Center,
Abstract
Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.Org: University of Texas MD Anderson Cancer Center, Cleveland Clinic Foundation, St. Joseph Heritage Health, Ohio State University Wexner Medical Center, Mayo Clinic,
Abstract
A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.Org: H. Lee Moffitt Cancer Center and Research Institute, Ohio State University Wexner Medical Center, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, Roswell Park Comprehensive Cancer Center, University of Washington, Cancer Vaccine Institute,
Abstract
Post-marketing surveillance safety analysis of patients with CNS malignancies treated with tumor treating fields (TTFields) therapy between 2011–2022.Org: Mayo Clinic Cancer Center, Thomas Jefferson University, New York-Presbyterian/Columbia University Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute,
Abstract
A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.Org: Vanderbilt University Medical Center, Hunstman Cancer Hospital, University of Utah Health, University of Utah, University of California Irvine, University of Pittsburgh Medical Center (UPMC),
Abstract
Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines.Org: H. Lee Moffitt Cancer Center and Research Institute, M2GEN, Huntsman Cancer Institute at the University of Utah, Stephenson Cancer Center, Ohio State University Wexner Medical Center,
Abstract
Time to treatment in inflammatory breast cancer: Experience from a single institution.Org: Ohio State University Wexner Medical Center, Center for Biostatistics in the Department of Biomedical Informatics, The Ohio State University - James Cancer Hospital, Ohio State University Comprehensive Canvcer Hospital,
Abstract
Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center,
Abstract
Associations of frailty with overall survival (OS) and functional decline among older adults with non–small-cell lung cancer (NSCLC) receiving chemotherapy, immunotherapy, and/or targeted therapy.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Ohio State University Wexner Medical Center, University of Rochester Medical Center,
Abstract
Comparative assessment of manual chart review and patient-level adverse drug event identification using artificial intelligence in evaluating immunotherapy‑related adverse events (irAEs).Org: The Ohio State University - James Cancer Hospital, Department of Biomedical Informatics, The Ohio State University, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
Evaluating depth of disparities in relation to relative survival rates: Analysis of SEER data.Org: Ohio State University Wexner Medical Center, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Cancer Center, The Ohio State University - James Cancer Hospital,
Abstract
Tumor lysis syndrome in solid tumors: A retrospective cohort study of the National Inpatient Sample from 2016 to 2019.Org: University of California Riverside, Crozer-Chester Medical Center, Hackensack Meridian Ocean University Medical Center, Ohio State University Wexner Medical Center,
Abstract
Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.Org: Ohio State University Wexner Medical Center, Columbus, OH, Yale School of Medicine, Madison, CT, The Ohio State University Wexner Medical Center,
Abstract
Rates of hematologic toxicity in WBRT vs SRS.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, The Ohio State University Wexner Medical Center, Columbus, OH, OHB Neonatology, Ohio State University Wexner Medical Center,
Abstract
Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI).Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,
Abstract
Real world outcomes of patients treated with first line chemo-immunotherapy (IO) for small cell lung cancer (SCLC): Impact of brain metastases and patterns of subsequent therapy.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Adena Health System, The Ohio State College of Medicine, Center for Biostatistics and Department of Biomedical Informatics,
Abstract
Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital & Solove Research Institute, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,
Abstract
Immune checkpoint inhibitors therapy in advanced bladder carcinoma: A meta-analysis of phase III randomized controlled trials.Org: Community Hospital of San Bernardino, University of California Riverside, Trumbull Regional Medical Center, Hackensack Meridian Ocean University Medical Center, University of California Berkeley, School of Public Health, Berkeley, CA,
Abstract
Chondrosarcoma: The OSU experience.Org: The Ohio State University Medical Center, The Ohio State University - James Cancer Hospital, Ohio State University James Cancer Hospital Department of Radiation Oncology, Ohio State University Hospital, The Ohio State University - James Cancer Hospital and Solove Research Institute,
Abstract
Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,
Abstract
Breast cancer disparities: A literature review of the last five years.Org: Hackensack Meridian Ocean University Medical Center, University of California Riverside, University of California Los Angeles, California University of Science and Medicine, Open Health Systs Lab,
Abstract
Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva).Org: Ohio State University Wexner Medical Center, Adena Health System, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Ohio State University James Cancer Hospital Department of Radiation Oncology,
Abstract
A retrospective study of Merkel cell carcinoma treated at The Ohio State University (OSU) in the last 20 years.Org: Ohio State University Wexner Medical Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University - James Cancer Hospital and Solove Research Institute,
Abstract
Clear cell sarcoma: The OSU experience.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Medical Center, The Ohio State University James Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Ohio State University Wexner Medical Center,